Choksi Laborator

Which are the latest news on Choksi Laborator?

Should I buy, sell or hold Choksi Laboratories Ltd?

Why is Choksi Laboratories Ltd falling/rising?

As of 18-Jul, Choksi Laboratories Ltd's stock price is at Rs 107.00, down 4.8%, and has significantly underperformed the Sensex with declines of 12.22% over the past week and 44.76% over the past year. The stock is in a bearish trend, trading below all major moving averages, despite a slight increase in investor participation.

As of 18-Jul, Choksi Laboratories Ltd's stock price is falling, currently at Rs 107.00, which reflects a decrease of Rs 5.4 or 4.8%. The stock has underperformed significantly against the benchmark Sensex, with a decline of 12.22% over the past week, 14.40% over the past month, and a staggering 44.76% over the past year. Additionally, the stock has been on a downward trend, having fallen consecutively for the last two days, resulting in an overall drop of 8.55% during this period.<BR><BR>Today, the stock reached an intraday low of Rs 106.8, indicating a loss of 4.98% at its lowest point. It is also trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. Although there has been a slight increase in investor participation, with delivery volume rising by 6.17% against the 5-day average, the overall performance remains weak, as the stock has underperformed its sector by 3.91%. These factors collectively contribute to the stock's decline.

How big is Choksi Laborator?

As of 10th June, Choksi Laboratories Ltd has a market capitalization of 83.00 Cr and reported net sales of 46.00 Cr and a net profit of 1.97 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Choksi Laboratories Ltd has a market capitalization of 83.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 46.00 Cr, while the sum of Net Profit for the same period is 1.97 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 23.60 Cr, and Total Assets amount to 64.79 Cr.

Who are in the management team of Choksi Laborator?

The management team of Choksi Laborator includes Sunil Choksi (Managing Director & CEO), Stela Choksi (Whole-time Director), Vyangesh Choksi (Whole Time Director & CFO), Himik Choksi (Whole-time Director), and several independent directors, along with Prakhar Dubey as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Choksi Laborator includes the following individuals:<BR><BR>1. **Sunil Choksi** - Managing Director & CEO<BR>2. **Stela Choksi** - Whole-time Director<BR>3. **Vyangesh Choksi** - Whole Time Director & CFO<BR>4. **Himik Choksi** - Whole-time Director<BR>5. **Sudarshan Shastri** - Independent Director<BR>6. **N K Mani** - Independent Director<BR>7. **Raghmendra Singh** - Independent Director<BR>8. **Meenaxi Patidar** - Independent Director<BR>9. **Prakhar Dubey** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Choksi Laborator?

Choksi Laborator's peers include Star Imaging, Bilcare, Aspira Pathlab, Royal Sense, Shree Pacetronix, Bandaram Pharma, Amkay Products, and Aakaar Medical. While Royal Sense shows excellent growth and capital structure, Choksi Laborator has below average management risk and capital structure, with a 1-year return of -35.73%.

Peers: The peers of Choksi Laborator are Star Imaging, Bilcare, Aspira Pathlab, Royal Sense, Shree Pacetronix, Bandaram Pharma, Amkay Products, Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, while Good management risk is found at Royal Sense, Shree Pacetronix, Amkay Products, and Aakaar Medical, and the rest have Below Average management risk. Growth is Excellent at Royal Sense, Good at Choksi Laborator, Shree Pacetronix, Bandaram Pharma, and Aakaar Medical, while Below Average growth is seen at Bilcare, Aspira Pathlab, and the rest. Capital Structure is Excellent at Star Imaging, Good at Royal Sense, Shree Pacetronix, and Amkay Products, while Below Average capital structure is found at Choksi Laborator, Bilcare, Aspira Pathlab, Bandaram Pharma, and the rest.<BR><BR>Return Snapshot: Aspira Pathlab has the highest 1-year return at 100.85%, while Bilcare has the lowest at -24.68%, with Choksi Laborator's 1-year return at -35.73% being lower than both. Additionally, Royal Sense, Shree Pacetronix, Bandaram Pharma, and Amkay Products all have negative six-month returns.

What does Choksi Laborator do?

Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare sector, with a market cap of INR 83 Cr and reported net sales of 13 Cr and net profit of 1 Cr for the quarter ending March 2026. The company has a P/E ratio of 46.00 and a debt-equity ratio of 1.20.

Overview:<BR>Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare services industry and operates within the micro-cap market.<BR><BR>History:<BR>Incorporated on 29 January 1993, Choksi Laboratories Ltd has been providing its services since its establishment. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 13 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 83 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 46.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.20 <BR>Return on Equity: 6.69% <BR>Price to Book: 3.24 <BR><BR>Contact Details:<BR>Address: Survey no 9/1 Gram Kumerdi, Near to Tulshiyana Indl Park Indore Madhya Pradesh : 452010 <BR>Email: compliance_officer@choksi.com <BR>Website: http://www.choksilab.com

Are Choksi Laboratories Ltd latest results good or bad?

Choksi Laboratories Ltd's latest Q4 FY26 results show a significant net profit increase of 232.26% and revenue growth of 12.46%, but concerns remain due to low return on equity (6.50%) and a high debt-to-EBITDA ratio (4.91), indicating underlying financial weaknesses. Overall, while there are positive signs, the results are mixed and warrant caution for investors.

Choksi Laboratories Ltd's latest results for Q4 FY26 show a mixed picture. On the positive side, the company reported a net profit of ₹1.03 crores, which is a significant increase of 232.26% compared to the previous quarter. Additionally, revenue grew by 12.46% year-on-year, reaching ₹12.82 crores, and the operating margin improved to 28.39%, up from 24.49% in the previous quarter.<BR><BR>However, there are notable concerns. The return on equity (ROE) remains low at 6.50%, indicating weak capital efficiency. The company also has a high debt-to-EBITDA ratio of 4.91 times, which raises questions about its financial stability. Furthermore, while the quarterly results show improvement, the annual profit stagnated at ₹1.00 crore, unchanged from the previous year, suggesting challenges in translating revenue growth into meaningful profit expansion.<BR><BR>In summary, while there are positive signs in the recent quarterly performance, underlying structural weaknesses and high leverage indicate that the overall results are not entirely favorable. Investors should weigh these factors carefully.

When is the next results date for Choksi Laboratories Ltd?

Choksi Laboratories Ltd will announce its results on 25 May 2026.

Choksi Laboratories Ltd is scheduled to declare its results on 25 May 2026.

How has been the historical performance of Choksi Laborator?

Choksi Laborator has experienced growth in net sales and operating income from Mar'21 to Mar'25, but its profitability metrics, including profit before and after tax, have fluctuated significantly. The company needs to focus on cost management and operational efficiency despite improved cash flow from operating activities.

Answer:<BR>The historical performance of Choksi Laborator shows a mixed trend over the years, with notable fluctuations in revenue and profitability.<BR><BR>Breakdown:<BR>Choksi Laborator's net sales have shown a consistent upward trajectory, increasing from 25.69 Cr in Mar'21 to 41.78 Cr in Mar'25. Total operating income followed a similar pattern, rising from 28.49 Cr in Mar'20 to 41.78 Cr in Mar'25. The company's operating profit (PBDIT) has also improved, reaching 11.30 Cr in Mar'25 from 3.17 Cr in Mar'20, although the operating profit margin has slightly decreased from 29.73% in Mar'23 to 26.88% in Mar'25. Profit before tax fluctuated significantly, peaking at 3.72 Cr in Mar'23 before dropping to 2.15 Cr in Mar'25. Profit after tax also saw a decline from 3.21 Cr in Mar'23 to 1.52 Cr in Mar'25. The company's total liabilities increased from 59.49 Cr in Mar'23 to 64.79 Cr in Mar'25, while total assets rose from 59.49 Cr to 64.79 Cr in the same period. Cash flow from operating activities improved to 11.00 Cr in Mar'25, maintaining stability compared to previous years. Overall, while Choksi Laborator has shown growth in sales and operating income, its profitability metrics have experienced volatility, indicating a need for strategic focus on cost management and operational efficiency.

Is Choksi Laborator overvalued or undervalued?

As of October 13, 2025, Choksi Laborator is rated attractive but considered overvalued with high valuation ratios, including a PE of 85.25, despite strong stock performance, especially when compared to peers like Apollo Hospitals and Max Healthcare.

As of 13 October 2025, the valuation grade for Choksi Laborator has moved from very attractive to attractive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 85.25, while the Price to Book Value is 5.42, and the EV to EBIT is 33.62, all indicating a premium valuation compared to its peers.<BR><BR>In comparison, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.2 and an EV to EBITDA of 36.12. Max Healthcare, rated as very expensive, has a PE ratio of 92.33, but its high valuation does not justify the premium over Choksi Laborator. Despite Choksi's impressive stock performance, with a year-to-date return of 144.57% compared to the Sensex's 5.36%, the elevated valuation ratios suggest that the stock may be overvalued in the current market environment.

Who are the top shareholders of the Choksi Laborator?

The top shareholders of Choksi Laborator include promoter Sunil Choksi with 7.51% and public shareholder Sachin Seth with 3.96%. Individual investors hold 52.67%, while foreign institutional investors own 1.94%, and there are no mutual funds invested in the company.

The top shareholders of Choksi Laborator include Sunil Choksi, who is the promoter with the highest holding at 7.51%. Following him, Sachin Seth is the highest public shareholder with a stake of 3.96%. Additionally, individual investors collectively hold a significant portion of the company at 52.67%. The company also has 1.94% held by foreign institutional investors (FIIs), but there are no mutual funds currently invested in it.

What is the technical trend for Choksi Laborator?

As of June 3, 2025, Choksi Laborator's technical trend has shifted to bullish, supported by strong daily moving averages and monthly indicators, despite some mildly bearish signals on the weekly MACD and KST.

As of 3 June 2025, the technical trend for Choksi Laborator has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands confirm a bullish trend. Despite the weekly MACD and KST showing mildly bearish signals, the monthly MACD and KST are bullish, reinforcing the overall positive outlook. Dow Theory also indicates a bullish trend on both weekly and monthly time frames. The stock has shown significant returns compared to the Sensex, further highlighting its strength in the market.

Has Choksi Laborator declared dividend?

No Dividend History Available